Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2013-005542-11-BG
EUCTR2013-005542-11-BGActive, not recruitingPhase 1

A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared with Rituximab in Subjects with CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL) - Not Applicable

Amgen Inc.0 sites250 target enrollmentStarted: September 10, 2014Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
250
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Inclusion Criteria

  • •Males and females 18 years of age and older
  • •Histological confirmed (by lymph node or extranodal region biopsy), Grade 1, 2, 3a follicular B-cell NHL expressing CD20 within 12 months before randomization
  • •Stage 2, 3, or 4 (per Cotswold’s Modification of Ann Arbor Staging System) with measurable disease (per International Working Group)
  • •subjects must have a baseline scan (computed tomography [CT]) of the neck (if palpable lymph node > 1.0 cm), chest, abdomen, and pelvis to assess disease burden within 6 weeks before randomization
  • •subjects must have had a baseline bone marrow biopsy within 12 months before randomization. Previously confirmed positive bone marrow involvment does not need to be repeated for purposes of screening.
  • •Low tumor burden based on the Groupe d'Etudes des Lymphomes Folliculaires (GELF) criteria
  • •- largest nodal or extranodal mass = 7 cm
  • •- no more than 3 nodal sites with diameter > 3 cm
  • •- no splenomegaly > 16 cm by CT scan and no symptomatic splenomegaly
  • •- no significant pleural or peritoneal serous effusions by CT
  • •- lactate dehydrogenase = upper limit of normal (ULN)
  • •- no B symptoms (night sweats, fever [temperature > 38 C], weight loss > 10% in the previous 6 months)
  • •5. Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1.
  • •Blood counts:
  • •absolute neutrophil count (ANC) = 1.5 x 109 /L (1,500/µL)
  • •lymphocytes < 1.5 x the ULN
  • •platelets = 100 x 109 /L (100,000/µL)
  • •hemoglobin = 10.0 g/dL
  • •Adequate hepatic function as defined by:
  • •aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 × ULN
  • •Adequate renal function as defined by creatinine < 1.5 x ULN or estimated creatinine clearance = 50 mL/min calculated by the Cockcroft-Gault method
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 125
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 125

Exclusion Criteria

  • •Diffuse large cell component and/or Grade 3 follicular NHL
  • •History or known presence of central nervous system metastases
  • •Malignancy other than NHL within 5 years (except treated in-situ cervical cancer, or squamous or basal cell carcinoma of the skin)
  • •Any of the following in the 6 months before randomization:
  • •clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure [New York Heart Association = Class III], serious uncontrolled cardiac arrhythmia); peripheral vascular disease, cerebrovascular accident, or transient ischemic attack in the previous 6 months
  • •Medically uncontrolled hypertension or systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg
  • •Known active or history of active tuberculosis (TB)
  • •Positive for hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C virus antibody at screening
  • •Known to be human immunodeficiency virus positive
  • •Recent infection requiring a course of systemic anti-infective agents that was completed = 7 days before randomization (with the exception of uncomplicated urinary tract infection)
  • •Other investigational procedures that can impact the study data, results, or patient safety while participating in the study are excluded; participation in observational studies is allowed.
  • •Subject is currently enrolled in or has not yet completed at least 30 days or 5 half-lives (whichever is longer) since ending other investigational device or drug study(s), including vaccines, or subject is receiving other investigational agent(s)
  • •Previous use of either commercially available or investigational chemotherapy, biological, or immunological therapy for NHL (including rituximab or biosimilar rituximab, or other anti-CD20 treatments)
  • •Systemic corticosteroid use within 3 months before randomization (inhaled are allowable)
  • •Live vaccines within 28 days prior to the first dose of IP
  • •History of neurologic symptoms suggestive of central nervous system demyelinating disease
  • •Woman of childbearing potential who is pregnant or is breastfeeding
  • •Woman of childbearing potential who does not consent to use highly effective methods of birth control (eg, true abstinence, sterilization, birth control pills, Depo Provera injections, or contraceptive implants) during treatment and for an additional 12 months after the last administration of the protocol specified-treatment
  • •Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control (eg, true abstinence, vasectomy, or a condom in combination with hormonal birth control or barrier methods used by the woman) during treatment and for an additional 12 months after the last administration of the protocol specified treatment
  • •Subject has known sensitivity to any of the products to be

Investigators

Sponsor
Amgen Inc.

Similar Trials

Active, not recruiting
Phase 1
The trial is designed to determine the efficacy and safety of ABP 798 compared with rituximab in subjects with CD 20 positive B-cell non Hodgkin lymphoma
EUCTR2013-005542-11-GRAmgen Inc.250
Active, not recruiting
Phase 1
The trial is designed to determine the efficacy and safety of ABP 798 compared with rituximab in subjects with CD 20 positive B-cell non Hodgkin lymphoma
EUCTR2013-005542-11-FRAmgen Inc.250
Active, not recruiting
Phase 1
The trial is designed to determine the efficacy and safety of ABP 798 compared with rituximab in subjects with CD 20 positive B-cell non Hodgkin lymphomaCD20 positive B-cell non-Hodgkin lymphomaMedDRA version: 17.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disorders
EUCTR2013-005542-11-ESAmgen Inc.250
Active, not recruiting
Phase 2
A clinical study to evaluate the efficacy, safety and tolerability of XtraBosTM (Boswellia Serrata Extract) in patients with osteoarthritis associated with hypertension or neuropathic pain, or sleep disorder.
CTRI/2023/07/055345Dr Willmar Schwabe India Pvt Ltd
Active, not recruiting
Not Applicable
The trial is designed to determine the efficacy and safety of ABP 798 compared with rituximab in subjects with CD 20 positive B-cell non Hodgkin lymphoma
EUCTR2013-005542-11-ITAmgen Inc.250